Looking through last years ann report I found the following comment interesting:
"We believe that the price of Novogen stock does not recognise the underlying value of phenoxodiol within the Company. And an independent expert valuation of phenoxodiol clearly showed that such a disparity exists between the price of Novogen shares (or market capitalisation) and the current value of phenoxodiol."
Note this was before recent positive developments like the deal struck with Yale University and the completion of Stage I Clinical trials.
NRT Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held